Efficiency analysis of ziprasidone combined with chlorpromazine in treatment of elderly patients with schizophrenia

XI Lingyan; JIN Guixing; ZHANG Suyun; HUANG Xiuqin; LI Ziyu

doi:10.7619/jcmp.20211029

Journal of Clinical Medicine in Practice > 2021 > 25(16): 116-119. > DOI: 10.7619/jcmp.20211029

XI Lingyan, JIN Guixing, ZHANG Suyun, HUANG Xiuqin, LI Ziyu. Efficiency analysis of ziprasidone combined with chlorpromazine in treatment of elderly patients with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2021, 25(16): 116-119. DOI: 10.7619/jcmp.20211029

Citation:

PDF (598 KB)

Efficiency analysis of ziprasidone combined with chlorpromazine in treatment of elderly patients with schizophrenia

1.
Department of Psychiatry, Hengshui City Psychiatric Hospital in Hebei Province, Hengshui, Hebei, 053800
2.
Department of Mental Health, the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050031

More Information

Received Date: March 10, 2021
Available Online: June 08, 2021
Published Date: August 27, 2021

Graphical Abstract

Abstract

Abstract

Objective To observe the efficacy of ziprasidone combined with chlorpromazine in the treatment of elderly patients with schizophrenia.
Methods Totally 100 elderly patients with schizophrenia were randomly divided into control group and combined group, with 50 cases in each group. The control group was treated with chlorpromazine, and the combined group was treated with ziprasidone and chlorpromazine. Mental symptoms, cognitive function, neurotrophic factors, electrocardiogram, blood potassium, blood magnesium and efficiency as well as adverse reactions were compared between the two groups.
Results After treatment, the score of Mini-mental State Examination (MMSE), the score of Stroop test, continuous operation test and digit symbol coding test, levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and total effective rate in the combined group were significantly higher than those in the control group, while the score of Positive and Negative Symptom Scale (PANSS), score of connection test A and levels of neuron specific enolase (NSE), hand-type calcium binding protein (S100b) and myelin basic protein (MBP) were significantly lower than those in the control group (P < 0.05).
Conclusion Ziprasidone combined with chlorpromazine can improve the clinical symptoms of elderly patients with schizophrenia, the abnormal expressions of NGF, BDNF and other neurotrophic factors, repair damaged neurons, and do not affect the body electrolyte balance.

FullText(HTML)

References (16)

References

[1]	TOMASIK J, RAHMOUNE H, GUEST P C, et al. Neuroimmune biomarkers in schizophrenia[J]. Schizophr Res, 2016, 176(1): 3-13. doi: 10.1016/j.schres.2014.07.025
[2]	HAN D, SHI S X, LUO H. The therapeutic effect of quetiapine on cognitive impairment associated with 5-HT1A presynaptic receptor involved schizophrenia[J]. J Integr Neurosci, 2019, 18(3): 245-251. doi: 10.31083/j.jin.2019.03.186
[3]	CHIOU Y J, HUANG T L. Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode schizophrenia: Effects of antipsychotics[J]. World J Biol Psychiatry, 2017, 18(5): 382-391. doi: 10.1080/15622975.2016.1224925
[4]	张中华, 庾光丹, 肖岚. 抗精神病药在精神分裂症表观遗传调控中的研究进展[J]. 中国神经精神疾病杂志, 2019, 45(3): 186-189. doi: 10.3969/j.issn.1002-0152.2019.03.014
[5]	许俊杰, 侯晓梅, 毕占魁. 氯氮平与氯丙嗪、利培酮三者治疗对精神分裂症患者肾功能的影响对比研究[J]. 中国临床医生杂志, 2016, 44(2): 67-68. doi: 10.3969/j.issn.2095-8552.2016.02.022
[6]	付旭, 秦晓霞. 氯氮平与氯丙嗪对维持治疗期老年精神分裂症患者认知功能的影响分析[J]. 中国医学前沿杂志: 电子版, 2016, 8(12): 145-148. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY201612046.htm
[7]	张艺, 郭春锋. 不同抗精神病药物对精神分裂症患者心电图的影响[J]. 安徽医学, 2018, 39(2): 193-195. doi: 10.3969/j.issn.1000-0399.2018.02.017
[8]	王晓良, 沈婷, 王飚, 等. 齐拉西酮和奥氮平合并无抽搐电休克对精神分裂症的疗效和安全性及代谢影响的对照研究[J]. 中国药物与临床, 2016, 16(2): 282-285. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC201602062.htm
[9]	王章元, 贾小玲, 张青青, 等. 齐拉西酮和奥氮平对老年精神分裂症患者脂糖代谢的影响[J]. 中国老年学杂志, 2016, 36(9): 2242-2244. doi: 10.3969/j.issn.1005-9202.2016.09.093
[10]	陈莹, 蔡靓, 徐炯炯, 等. 齐拉西酮胶囊对男性青少年首发精神分裂症患者PRL及FINS的敏感性调控机制[J]. 中国生化药物杂志, 2016, 36(9): 39-41. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYW201609009.htm
[11]	辛一帆, 李光梅, 郑兴华. 精神分裂症患者社会支持程度与血清神经功能指标水平及阴性症状、抑郁症状的相关性[J]. 神经疾病与精神卫生, 2019, 19(4): 371-376. doi: 10.3969/j.issn.1009-6574.2019.04.011
[12]	朱桂东, 宋清海, 徐伟杰, 等. 齐拉西酮联合奥氮平对老年难治性精神分裂症患者症状及血清瘦素和脑源性神经营养因子水平的影响[J]. 中国慢性病预防与控制, 2019, 27(3): 219-222. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXB201903015.htm
[13]	杨明杰. 精神分裂症患者血清蛋白因子水平的表达特点及其意义[J]. 解放军预防医学杂志, 2018, 36(9): 1207-1210. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYX201809034.htm
[14]	蓝永乐, 李介华, 温雪仪, 等. 血清Hcy和NSE水平与首发精神分裂症患者认知功能的相关性分析[J]. 检验医学与临床, 2018, 15(18): 2791-2794. doi: 10.3969/j.issn.1672-9455.2018.18.031
[15]	杨巧云. 帕罗西汀联合奥氮平治疗对精神分裂症患者S100B、S100β及repetin的影响[J]. 实用临床医药杂志, 2018, 22(7): 31-34. doi: 10.7619/jcmp.201807008
[16]	沈迪文, 黄莹, 任方芳. 精神分裂症患者血清NGF-β、EGF、MBP与认知功能相关性分析[J]. 医学临床研究, 2019, 36(6): 1188-1189. doi: 10.3969/j.issn.1671-7171.2019.06.055

Cited By

Cited by

Periodical cited type(5)

1.	林璐，颜晓璐，刘欢. 适应性领导力理论指导下框架干预模式对糖尿病周围神经病变患者血糖水平及治疗依从性的影响. 全科医学临床与教育. 2025(02): 181-183 .
2.	李霞，姚涛，王颖. 司美格鲁肽联合二甲双胍对2型糖尿病患者血清载脂蛋白B与载脂蛋白A1比值、网膜素-1及成纤维细胞生长因子-21的影响. 实用临床医药杂志. 2024(16): 83-87 . 本站查看
3.	欧阳建华，肖琴，谢芳钰，钟倩，刘爱连. 2型糖尿病周围神经病变与血清25-羟基维生素D_3的关系及其影响因素分析. 中国当代医药. 2024(27): 129-132 .
4.	许华娇，吴玲玲，杨云，张杰，张琦. ICU患者胰岛素静脉输注管理的最佳证据应用. 护理学杂志. 2024(21): 11-15 .
5.	王黎，阚琛，巩雪莹，张效科. 益肾活血方联合依帕司他片治疗肾虚血瘀型糖尿病周围神经病变的临床疗效观察. 中药新药与临床药理. 2024(11): 1788-1793 .

Other cited types(3)

Get Citation

PDF

XML

Article views (433) PDF downloads (13) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Efficiency analysis of ziprasidone combined with chlorpromazine in treatment of elderly patients with schizophrenia

Abstract

References

Cited by

Periodical cited type(5)

Other cited types(3)

Catalog

Export File

Citation

Format

Content